Ireland· IE-PA-PA1122/028/001
Parecoxib 40 mg powder and solvent for solution for injection
A parecoxib product containing parecoxib sodium, registered in Ireland by Noridem Enterprises Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Parecoxib is registered in 13 of 19 countries.
Countries holding a registration under ATC M01AH04 (parecoxib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Parecoxib · ATC M01AH04
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- United Kingdom
The record
At a glance
HPRA (Ireland)- Active substance
- Parecoxib Sodium
- Manufacturer
- Noridem Enterprises Limited
- Country
- Ireland (IE)
- ATC code
- M01AH04
- ATC class
- Parecoxib
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA1122/028/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Parecoxib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandDynastatPfizer Limited
- United KingdomDynastat 40mg powder and solvent for solution for injection vialsPfizer Ltd
- GermanyParecoxib ChenponChenpon De Gmbh
- SwedenDynastat 40 mg Pulver och vätska till injektionsvätska, lösningPfizer Europe MA EEIG
- NetherlandsDynastat 40 mg, poeder en oplosmiddel voor oplossing voor injectiePfizer Europe MA EEIG
- CzechiaDYNASTATPfizer Europe MA EEIG, Bruxelles
- NorwayDynastatPfizer Europe MA EEIG (1)
- IcelandDynastatPfizer Europe MA EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Germany · Parecoxib Chenpon, Parecoxib Noridem
- Denmark · Parecoxib Macure, Parecoxib Noridem
- Finland · Parecoxib Macure
- United Kingdom (Northern Ireland) · Parecoxib Aspire Pharma, Parecoxib Noridem Enterprises
- Greece · Coxidem, Pyrixip
- Iceland · Dynastat, Parecoxib Macure
- Liechtenstein · Dynastat
- Malta · Parecoxib Noridem
- Netherlands · Parecoxib Chenpon, Parecoxib Seacross
- Norway · Dynastat, Parecoxib Macure
- Portugal · Parecoxib Noridem, Pyrixip
- Romania · Parecoxib Noridem
- Sweden · Parecoxib Macure, Parecoxib Noridem
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ded5a6d5-9ac5-4f0f-bc34-1ef60fc80d9c GET /v1/drugs/ded5a6d5-9ac5-4f0f-bc34-1ef60fc80d9c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"routes": [
"Intramuscular use",
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"M01AH04"
],
"strength": null,
"pa_number": "PA1122/028/001",
"substances": [
"Parecoxib Sodium"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "08/10/2021",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about parecoxib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.